Moreover, the anti-leukemic agent decita-bine downregulates DNMT1, but has no effect on DNMT3a/b expression, supporting the potential importance of DNMT1 as a target for the treatment of AML [2]. This evidence concerns the gene DNMT1 and acute myeloid leukemia.